# Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

> **NCT04466150** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **University of California, San Francisco** · enrollment: 30 (estimated)

## Conditions studied

- Relapsing Multiple Sclerosis
- Clinically Isolated Syndrome

## Interventions

- **DRUG:** Ocrelizumab

## Key facts

- **NCT ID:** NCT04466150
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-30
- **Primary completion:** 2026-12
- **Final completion:** 2027-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04466150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04466150, "Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04466150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*